These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Assan R; Feutren G; Sirmai J; Laborie C; Boitard C; Vexiau P; Du Rostu H; Rodier M; Figoni M; Vague P Diabetes; 1990 Jul; 39(7):768-74. PubMed ID: 2191883 [TBL] [Abstract][Full Text] [Related]
3. Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Dupre J; Jenner MR; Mahon JL; Purdon C; Rodger NW; Stiller CR Diabetes; 1991 May; 40(5):598-604. PubMed ID: 2022304 [TBL] [Abstract][Full Text] [Related]
4. Natural course of remission in IDDM during 1st yr after diagnosis. Martin S; Pawlowski B; Greulich B; Ziegler AG; Mandrup-Poulsen T; Mahon J Diabetes Care; 1992 Jan; 15(1):66-74. PubMed ID: 1737543 [TBL] [Abstract][Full Text] [Related]
5. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. Finegood DT; Hramiak IM; Dupre J J Clin Endocrinol Metab; 1990 Jun; 70(6):1538-49. PubMed ID: 2189884 [TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Rakotoambinina B; Timsit J; Deschamps I; Laborde K; Jos J; Boitard C; Assan R; Robert JJ Diabetes Care; 1995 Nov; 18(11):1487-90. PubMed ID: 8722075 [TBL] [Abstract][Full Text] [Related]
7. Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients. Burcelin RG; Eddouks M; Beylot M; Normand S; Boitard C; Feutren G; Landais P; Riou JP; Girard JR; Bach JF Diabetes Care; 1993 Jun; 16(6):881-8. PubMed ID: 8325202 [TBL] [Abstract][Full Text] [Related]
8. Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus. Giordano C; Pantŏ F; Amato MP; Sapienza N; Pugliese A; Galluzzo A J Autoimmun; 1990 Oct; 3(5):611-7. PubMed ID: 2252529 [TBL] [Abstract][Full Text] [Related]
9. Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients. Agner T; Damm P; Binder C Diabetes Care; 1987; 10(2):164-9. PubMed ID: 3556104 [TBL] [Abstract][Full Text] [Related]
10. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Snorgaard O; Lassen LH; Binder C Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301 [TBL] [Abstract][Full Text] [Related]
11. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Alejandro R; Feldman EC; Bloom AD; Kenyon NS Diabetes; 1989 Jun; 38(6):698-703. PubMed ID: 2656339 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes; 1988 Nov; 37(11):1574-82. PubMed ID: 2903105 [TBL] [Abstract][Full Text] [Related]
13. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Bougnères PF; Landais P; Boisson C; Carel JC; Frament N; Boitard C; Chaussain JL; Bach JF Diabetes; 1990 Oct; 39(10):1264-72. PubMed ID: 2210078 [TBL] [Abstract][Full Text] [Related]
14. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients. Simonson DC; Delprato S; Castellino P; Groop L; DeFronzo RA Diabetes; 1987 Feb; 36(2):136-46. PubMed ID: 3100365 [TBL] [Abstract][Full Text] [Related]
15. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069 [TBL] [Abstract][Full Text] [Related]
16. Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year. Moncada E; Subirá ML; Oleaga A; Goñi F; Sánchez-Ibarrola A; Monreal M; Sevilla M; Goñi MJ; Yoldi A; Terán D J Autoimmun; 1990 Oct; 3(5):625-38. PubMed ID: 2252531 [TBL] [Abstract][Full Text] [Related]
17. Effects of methylprednisolone pulse therapy on insulin injections in patients with insulin-dependent diabetes mellitus. Satman I; Fiçicioğlu C; Karşidağ K; Yilmaz T; Dinçdağ N; Koca F; Odabaşi F; Aydin A; Devrim S; Haktan M Turk J Pediatr; 1996; 38(4):419-29. PubMed ID: 8993171 [TBL] [Abstract][Full Text] [Related]
18. Pathogenic mechanism of type 2 diabetes in Ghanaians--the importance of beta cell secretion, insulin sensitivity and glucose effectiveness. Amoah AG; Owusu SK; Schuster DP; Osei K S Afr Med J; 2002 May; 92(5):377-84. PubMed ID: 12108171 [TBL] [Abstract][Full Text] [Related]
19. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Lee WJ; Ser KH; Chong K; Lee YC; Chen SC; Tsou JJ; Chen JC; Chen CM Surgery; 2010 May; 147(5):664-9. PubMed ID: 20004451 [TBL] [Abstract][Full Text] [Related]
20. Normalization of insulin sensitivity and glucose homeostasis in type I diabetic pancreas transplant recipients: a 48-month cross-sectional study--a clinical research center study. Cottrell DA J Clin Endocrinol Metab; 1996 Oct; 81(10):3513-9. PubMed ID: 8855794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]